Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Abroad (travel likely)Recruiting

Conditions

Mild Cognitive Impairment · Alzheimer Disease · Dementia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MoCA Clinic and Institute, Greenfield Park, Quebec, Canada
Contact: Study coordinator (Joana Krieger) · joana.krieger@mocacognition.com · 450 672-7766
Contact: Study coordinator (Amy Dam) · amy.dam@mocacognition.com

Study leads

Ziad Nasreddine, MD
Principal Investigator
MoCA Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia

Mild Cognitive Impairment (MCI) · Dementia · Alzheimer Disease, Early Onset

Abroad (travel likely)Recruiting

Caserta, Italy

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Alzheimer Disease · Mild Cognitive Impairment · Dementia

Abroad (travel likely)RecruitingPHASE2

Englewood, United States

Study to Understand Novel Biomarkers in Researching Dementia

Alzheimer Disease · Mild Cognitive Impairment · Dementia

Abroad (travel likely)Recruiting

St Louis, United States

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

Cognitive Dysfunction · Alzheimer Disease · Mild Cognitive Impairment

Abroad (travel likely)Recruiting

Rio de Janeiro, Brazil